Video Experimental Relacionado
Updated: Apr 19, 2026
11:32
Analytical Determination of Mitochondrial Function of Excised Solid Tumor Homogenates
Published on: August 6, 2021
3.2K
La dependencia del acetato de los tumores
Sarah A Comerford1, Zhiguang Huang2, Xinlin Du2
1Department of Molecular Genetics, UT Southwestern Medical Center, Dallas, TX 75390, USA.
Cell
|December 20, 2014
Resumen
La enzima ACSS2 (acetil-CoA sintetasa 2) ayuda al crecimiento de los tumores mediante el uso de acetato. El bloqueo de ACSS2 redujo significativamente el tamaño del tumor en ratones, lo que lo sugiere.
Área de la Ciencia:
- La bioquímica es la bioquímica.
- Las vías metabólicas.
- Biología del cáncer Biología del cáncer.
Sus antecedentes:
- El acetil-CoA (AcCoA) es crucial para la energía celular, el crecimiento y la regulación génica.
- Los tumores con alta glucólisis o hipoxia dependen de AcCoA para la supervivencia.
- ACSS2 es una enzima clave en el metabolismo de AcCoA.
Objetivo del estudio:
- Para investigar el papel de la acetil-CoA sintetasa nucleocitosólica (ACSS2) en el metabolismo tumoral.
- Para determinar si ACSS2 es un objetivo terapéutico potencial para el cáncer.
Principales métodos:
- Se utilizaron ratones que carecían de la enzima ACSS2.
- La carga tumoral fue evaluada en dos modelos de carcinoma hepatocelular.
- Se midió la absorción celular de acetato y la incorporación en lípidos e histonas.
Principales resultados:
- Los ratones que carecían de ACSS2 mostraron una reducción significativa en la carga tumoral.
- La actividad de ACSS2 representó la mayor parte de la absorción celular de acetato.
- ACSS2 se expresa en una gran proporción de los tumores humanos.
Conclusiones:
- ACSS2 es una fuente crítica de AcCoA para los tumores, utilizando acetato.
- ACSS2 representa una vulnerabilidad metabólica dirigible en un amplio espectro de tumores.
- Dirigirse a ACSS2 puede ofrecer una nueva estrategia terapéutica para el tratamiento del cáncer.
Videos de Conceptos Relacionados
02:53Adaptive Mechanisms in Cancer Cells
7.6K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.6K
01:46Electron Transport Chain: Complex I and II
19.8K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
19.8K
01:24Phase II Reactions: Acetylation Reactions
1.1K
Acetylation, a phase II biotransformation reaction, introduces an acetyl group to drugs or their metabolites. Acetyltransferase enzymes facilitate this reaction, which resembles α-amino acid conjugation due to the addition of a functional group to the drug molecule.
The substrates for acetylation are typically drugs or their metabolites with an amino, sulfonamide, or hydrazine functional group. Acetylation can occur at several points in the drug molecule, including primary, secondary, and...
The substrates for acetylation are typically drugs or their metabolites with an amino, sulfonamide, or hydrazine functional group. Acetylation can occur at several points in the drug molecule, including primary, secondary, and...
1.1K
01:19Allosteric Proteins-ATCase
7.0K
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
7.0K
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
74
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
74
02:56Treatment Resistant Cancers
3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K